Regulatory · source year

2020 regulatory records

45 selected, source-linked regulatory records dated 2020. This is selective source coverage, not a complete timeline.

Dated records

45 selected records.

Peptide profiles

23 connected profiles.

Cited sources

45 distinct public records.

Cited chronology

Dated source records

All record types in 2020 →

December 2020

5 records

Setmelanotide

Federal Register notice 2020-27760

The Federal Register published notice 2020-27760, attributed to FDA and its parent HHS department, on 2020-12-17. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.

Source: Federal Register via GovInfo ↗

→

November 2020

4 records

Vasopressin

Federal Register notice 2020-26133

The Federal Register published notice 2020-26133, attributed to FDA and its parent HHS department, on 2020-11-25. Its official title is “Termination of the Food and Drug Administration's Unapproved Drugs Initiative; Request for Information Regarding Drugs Potentially Generally Recognized as Safe and Effective,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

October 2020

4 records

Daptomycin

Federal Register notice 2020-23439

The Federal Register published notice 2020-23439, attributed to FDA and its parent HHS department, on 2020-10-22. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

Calcitonin salmon

Federal Register notice 2020-23300

The Federal Register published notice 2020-23300, attributed to FDA and its parent HHS department, on 2020-10-21. Its official title is “Determination That BUTISOL SODIUM (Butabarbital Sodium) Oral Tablets, 15 Milligrams, 50 Milligrams, and 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

Source: Federal Register via GovInfo ↗

→

September 2020

3 records

August 2020

4 records

Bremelanotide

Federal Register notice 2020-18240

The Federal Register published notice 2020-18240, attributed to FDA and its parent HHS department, on 2020-08-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; VYLEESI,” and PeptideScanner's exact reviewed identity mapping connects the document to Bremelanotide.

Source: Federal Register via GovInfo ↗

→

July 2020

4 records

Vasopressin

Federal Register notice 2020-16649

The Federal Register published notice 2020-16649, attributed to FDA and its parent HHS department, on 2020-07-31. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

Terlipressin

Federal Register notice 2020-14719

The Federal Register published notice 2020-14719, attributed to FDA and its parent HHS department, on 2020-07-08. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin.

Source: Federal Register via GovInfo ↗

→

June 2020

2 records

May 2020

3 records

Nesiritide

Federal Register notice 2020-10367

The Federal Register published notice 2020-10367, attributed to FDA and its parent HHS department, on 2020-05-14. Its official title is “Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.

Source: Federal Register via GovInfo ↗

→

April 2020

3 records

March 2020

8 records

Liraglutide + 1 more

Federal Register notice 2020-04320

The Federal Register published notice 2020-04320, attributed to FDA and its parent HHS department, on 2020-03-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide and Semaglutide.

Source: Federal Register via GovInfo ↗

→

February 2020

2 records

January 2020

3 records